Ovarian Cancer

Ciphergen confirms use of its ProteinChip system

Published in Women's Health Weekly, April 18th, 2002

Ciphergen Biosystems, Inc., (CIPH) confirmed that the ovarian cancer detection study was conducted using Ciphergen's ProteinChip Biology System to discover and assay the patterns of proteins utilized in the study. The results were published in Lancet (Feb. 2002).

Undertaken by the U.S. National Cancer Institute and the U.S. Food and Drug Administration, this groundbreaking study discovered protein patterns found in the serum of 50 ovarian cancer patients that distinguished them from 50 women without the disease. These patterns were then used to screen another 116 serum samples, 50 from ovarian cancer patients and 66 from healthy women or women with nonmalignant...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-04-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry